+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 253 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are studying the effects and safety of alternating two chemotherapy treatments, gemcitabine plus nab-paclitaxel GnP and modified FOLFIRINOX mFOLFIRINOX, in patients with borderline resectable pancreatic ductal adenocarcinoma BR-PDAC. These treatments are FDA-approved for this condition, and alternating them aims to improve how well the cancer responds to therapy, increase the chance of successful tumor removal, and reduce the risk of cancer recurrence. Participants will receive GnP on days 1, 8, and 15 during cycles 1 and 3, and mFOLFIRINOX on days 1 and 15 during cycles 2 and 4, with each cycle lasting 28 days. This neoadjuvant chemotherapy is given before surgery, following recommendations by treating physicians. The study is a single-group, phase 2 clinical trial that evaluates this alternating treatment approach. During the study, participants will undergo contrast-enhanced CT scans of the chest, abdomen, and pelvis, as well as regular assessments of tumor response, surgical resection outcomes, and survival rates for up to one year. Researchers will monitor safety, treatment completion, dose changes, and cancer recurrence. The main measurement is one-year event-free survival. Participation lasts until surgery and follow-up evaluations, with data collected to assess the effectiveness and safety of the alternating chemotherapy regimen.

Age: 18Years +All GendersPhase 2
1 location
E

Actively Recruiting

Researchers are evaluating the use of PET imaging with the radioligand 18FPI-2620 to detect tau protein buildup in people with Alzheimers disease and control subjects. This open-label, multi-center, pivotal Phase 3 study compares imaging results during life to brain tissue analysis after death to assess the accuracy and safety of this diagnostic method. Participants will receive an intravenous injection of 18FPI-2620 at a dose of 185 MBq 20%. This study is non-randomized and single-group, focusing on the imaging procedure itself without placebo or alternative treatments. The study will continue until autopsy and brain tissue analysis are completed, with an average follow-up period of about one year. During the study, participants will undergo PET scans using 18FPI-2620. Researchers will assess the scans ability to correctly identify tau pathology related to Alzheimers disease by comparing them to post-mortem brain tissue analysis. The study includes safety monitoring and evaluation of the agreement between different readers interpreting the scans. Overall participation lasts until the participants death and brain autopsy, expected on average around one year after the scan.

Age: 50Years +All GendersPhase 3
25 locations
P

Actively Recruiting

Researchers are evaluating BMS-986500 as a treatment for people with advanced solid tumors, including advanced breast and ovarian cancer. This phase 1 study aims to assess BMS-986500 alone and in combination with other drugs in patients who have previously been treated with CDK46 inhibitors. The study focuses on understanding the safety and effects of BMS-986500 in these advanced cancer types. Participants will receive BMS-986500 either as a single treatment or combined with Palbociclib and Fulvestrant, depending on the study part. The study includes several parts, such as monotherapy dose escalation, combination dose escalation, pharmacodynamic sub-studies, and dose expansion phases. Treatments are given in specified doses on specified days, and the study monitors participants closely throughout these periods. During the study, participants will undergo regular assessments to track side effects, adverse events, and how the drug behaves in the body, including blood concentration over time. Researchers will monitor safety up to 28 days after the last dose and continue to observe some measures for up to approximately two years. The total duration of participation depends on the study part and treatment schedule.

Age: 18Years +All GendersPhase 1
21 locations
P

Actively Recruiting

Researchers are evaluating CPO301, an antibody drug conjugate, in adults with advanced or metastatic solid tumors who have progressed on prior treatments or are ineligible for standard therapy. This Phase 1 trial aims to assess the safety, tolerability, and optimal dosing of CPO301, as well as its pharmacokinetics, immunogenicity, and preliminary effectiveness, including its relationship to EGFR biomarker mutations. The study is sponsored by Conjupro Biotherapeutics, Inc. The trial has two parts. In Part A, patients receive escalating doses of CPO301 by intravenous injection every three weeks to identify the maximum tolerated dose or recommended phase 2 dose. In Part B, additional patients receive CPO301 at the dose determined safe and tolerable in Part A, focusing on those with non-small cell lung cancer with EGFR mutations and other tumor types. Treatment cycles last 21 days, and dose adjustments may be made based on safety assessments. Participants will provide informed consent, undergo screening to confirm eligibility, and attend study visits to receive CPO301 every three weeks until the study doctor decides to stop treatment. Researchers will monitor participants for disease progression every three months for up to two years. Safety, drug metabolism, immune response, and preliminary antitumor activity will be evaluated throughout the study, which is expected to last about one year for the primary outcomes.

Age: 18Years +All GendersPhase 1
14 locations
O

Actively Recruiting

Researchers are studying IAM1363 in a Phase 11b open-label trial involving participants with advanced cancers that have HER2 alterations. The study aims to evaluate the safety and early effectiveness of IAM1363 in these cancers, including cases with brain metastases. It is a multi-center trial sponsored by Iambic Therapeutics, Inc, designed to find appropriate dosing and assess potential benefits in patients with relapsed or refractory HER2-altered tumors. The study consists of four parts initial dose escalation of IAM1363 given alone, dose optimization to refine dosing, dose expansion to test the selected doses in specific tumor types, and combination cohorts where IAM1363 is given with other anti-cancer agents. Participants receive IAM1363 orally in 14- or 21-day cycles either alone or combined with drugs such as capecitabine, trastuzumab, zanidatamab, T-Dxd, pembrolizumab, carboplatin, or pemetrexed. Participants will be monitored through various assessments including measuring side effects, laboratory tests, electrocardiograms, and scans to evaluate tumor response. Researchers will track dose limiting toxicities, adverse events, pharmacokinetics, and tumor response rates over the course of the trial and follow-up, which may last up to 46 months. Safety and treatment modifications are closely observed through and after treatment completion.

Age: 18Years +All GendersPhase 1
53 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of oral brepocitinib in adults with lichen planopilaris, a condition affecting the scalp. This Phase 23 trial aims to understand how well this medication works compared to a placebo in treating active and symptomatic lichen planopilaris. The study is sponsored by Priovant Therapeutics, Inc. and uses a randomized, double-blind design to ensure reliable results. Participants are randomly assigned to receive either oral brepocitinib or a placebo. The study is conducted in parallel groups, with neither the participants nor the researchers knowing who receives the active drug or placebo. The treatment period lasts 24 weeks, during which the participants take the assigned oral medication. The main goal is to measure improvement in the Investigator Global Assessment IGA score by Week 24. Throughout the study, participants will be regularly monitored for safety and symptom changes. Researchers will assess the proportion of participants who achieve significant improvement in their IGA scores at Week 24 and track changes in symptom severity using a numerical rating scale. The total study duration extends until July 2029, allowing for thorough evaluation of treatment effects and safety over time.

Age: 18Years +All GendersPhase 2Phase 3
61 locations
P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
L

Actively Recruiting

Researchers are evaluating the long-term safety of lonapegsomatropin in children with growth hormone deficiency who are already being treated with this medication. This study is observational and aims to gather real-world safety data over time after the drug has been authorized for use. The focus is on monitoring potential risks such as the development of tumors and type 2 diabetes over a period of five years. Participants receive lonapegsomatropin, administered once weekly by subcutaneous injection as part of their usual care. The study does not involve additional interventions but observes patients who are already treated with this therapy. The observational period extends for at least five years to collect safety data and compare it with historical information from previous studies. During the study, researchers will monitor for the occurrence of benign and malignant tumors, type 2 diabetes, and other adverse events affecting the kidneys, liver, immune system, and nervous system. They will also track medication errors and measure the response of Insulin-like Growth Factor-1 IGF-1 to treatment. Participants are followed up regularly to collect this information, with the study lasting until March 2033.

Age: 1Year - 18YearsAll Genders
27 locations
T

Actively Recruiting

Researchers are evaluating a new way to promote exercise among breast cancer survivors who completed their main treatment within the last five years. This study compares an affect-based exercise prescription, which encourages participants to choose exercise that makes them feel good, with an effort-based prescription that focuses on exercise intensity. The study aims to see if participants will increase their moderate to vigorous physical activity and how satisfied they are with their assigned exercise approach. Participants are randomly assigned to one of two groups the affect-based exercise prescription or the effort-based exercise prescription. All participants meet twice with study staff to help them start increasing their weekly exercise and receive a core exercise promotion program covering safety, past experience, and strategies to overcome barriers. Each participant receives an exercise plan based on frequency, intensity, time, and type of exercise, with intensity guidance differing between groups. They are also given a smartwatch to help track their activity over the 12-week study. During the study, participants wear an activity monitor and complete brief surveys for 10 consecutive days at four time points before starting, and at 2, 6, and 12 weeks. Researchers measure daily moderate to vigorous physical activity using the ActiGraph accelerometer and assess participant satisfaction, study retention, acceptability of the exercise plans, and changes in exercise behavior through questionnaires. The total study duration is 12 weeks with regular assessments to understand the impact of these exercise prescriptions.

Age: 18Years +All GendersPhase Not Applicable
1 location
C

Actively Recruiting

Researchers are evaluating the combination of pembrolizumab and sacituzumab govitecan-hziy compared to standard chemotherapy treatments for patients with advanced urothelial cancer that has spread locally or to other parts of the body. This phase III trial aims to compare survival rates and other treatment responses between the new combination therapy and the usual care involving drugs like carboplatin, cisplatin, gemcitabine, docetaxel, or paclitaxel. The study also examines quality of life and side effects for both approaches. Participants are randomly assigned to one of two groups. One group receives standard chemotherapy treatments such as carboplatin or cisplatin with gemcitabine, or alternatively docetaxel or paclitaxel, given intravenously in cycles every 21 days for up to six cycles if tolerated. The other group receives pembrolizumab intravenously on day 1 and sacituzumab govitecan-hziy intravenously on days 1 and 8 of each 21-day cycle, continuing for up to 35 cycles or two years of pembrolizumab if there is no disease progression or unacceptable side effects. Throughout treatment, participants undergo blood tests and imaging scans like CT or MRI. Participants are followed closely during treatment with regular assessments including imaging and blood sample collection to monitor response and side effects. After treatment ends, follow-up visits occur at 30 days and then annually for five years to track overall survival and other health outcomes. The trial measures overall survival as the primary outcome and also evaluates progression-free survival, response rates, duration of response, adverse events, and quality of life aspects related to fatigue and bladder symptoms.

Age: 18Years +All GendersPhase 3
163 locations

1-10 of 253

1